Methods of reducing the levels of protoporphyrin IX in recombina

Details Methods of reducing the levels of protoporphyrin IX in recombina Methods of reducing the levels of protoporphyrin IX in recombina

1999-10-18

2000-10-24

Carlson, Karen Cochrane

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

435 691, 530385, C12P 2104, C12P 2106, C07K 14805

Patent

active

061365653

DESCRIPTION:

BRIEF SUMMARY
The present invention generally relates to methods of producing recombinant hemoglobin, and more particularly to methods of reducing the expression of hemoglobin containing protoporphyrin IX.


BACKGROUND OF THE INVENTION

It is not always practical or desirable to transfuse a patient with donated blood. In these situations, use of a red blood cell substitute is desirable. Such a product would need to transport oxygen, just as red blood cells do.
When patients lose blood, it is usually necessary to replace the entire fluid volume lost. However, it is not usually necessary to replace all of the lost hemoglobin. The primary goal of hemoglobin replacement therapy is to transport oxygen from the lungs to peripheral tissues. Hemoglobin administration also increases and maintains plasma volume and decreases blood viscosity. While many volume expanding colloid and crystalloid solutions are now marketed, none can transport oxygen. The only current therapy with this capability is human blood transfusion.
Genetic engineering techniques have allowed the expression of heterologous proteins in a number of biological expression systems, for example, insect cell lines, transgenic cells, yeast systems and bacterial systems. Expression of hemoglobin in particular has been demonstrated in transgenic pigs (Logan et al., WO 92/22646), yeast (De Angelo et al., WO 93/08831 and WO 91/16349; Hoffman et a., WO 90/13645), and the bacterial E. coli system (Hoffman et al., WO 90/13645). Although expression of hemoglobin in these heterologous systems can be achieved at useful levels, purification of the final product to the extreme level of purity required for practical use of hemoglobin remains difficult. Removal of contaminating isoforms of hemoglobin is particularly difficult in that these isoforms often co-purify with the desirable form of hemoglobin.
Hemoglobin (Hb) is a tetrameric protein molecule composed of two alpha and two beta globin units. Alpha and beta globin subunits associate to form two stable alpha/beta dimers, which in turn loosely associate to form the hemoglobin tetramer. Human hemoglobin Ao (also known as naturally occurring or native hemoglobin) is a heterotetramer composed of two alpha globin subunits (a.sub.1, a.sub.2) nd two beta globin subunits (b.sub.1, b.sub.2). There is no sequence difference between a.sub.1 and a.sub.2 or b.sub.1 and b.sub.2. In the unoxygenated ("deoxy", or "T" for "tense") state, the subunits form a tetrahedron. The a.sub.1 b.sub.1 and a.sub.2 b.sub.2 interfaces remain relatively fixed during oxygen binding, while there is considerable flux at the a.sub.1 b.sub.2 and a.sub.2 b.sub.1 interfaces. In the oxygenated ("oxy" or "R" or relaxed) state, the intersubunit distances are increased. The subunits are noncovalently associated by Van der Waals forces, hydrogen bonds and, for deoxy Hb, salt bridges.
In fully functional normal or native hemoglobin, a heme molecule is incorporated into each of the alpha and beta globins. Hence is a large organic molecule coordinated around an iron atom. Heme is also a cofactor in hemoglobin and is required to form soluble hemoglobin. A heme group that is lacking the iron atom is known as protoporphyrin IX (PIX) and is non-functional (cannot bind a ligand). PIX can be incorporated into one or more of the a and b subunits of hemoglobin, but the PIX-containing subunit lacks the ability to bind and release oxygen or other ligands. If all of the prosthetic groups are protoporphyrin IX rather than heme, then the hemoglobin cannot bind or release oxygen and therefore is functionless.
In E. coli and related bacteria, heme.sub.b (which is also known as "protoheme," "ferrous protoporphyrin IX" and also referred to herein as "heme") essential for respiration and for detoxification of reactive species of oxygen. Heme.sub.b serves as an essential cofactor for b-type cytochromes, catalase and peroxidase.
Biosynthesis of heme.sub.b occurs via a complex, branched pathway that involves up to twelve gene products. In non-recombinant E. coli cells, the accumulatin of large

REFERENCES:
patent: 5665829 (1997-09-01), Ryland et al.
patent: 5840851 (1998-11-01), Plommer et al.
Kazumasa Miyamoto, et al., "Isolation and Characterization of Visible Light-sensitive Mutants of Eschericia coli K12," Dec. 1990. pp. 393-398.
Kazumasa Miyamoto, et al., "Accumulation of protoporphyrin IX in ligh-sensitive mutants of Escherichia coli, " Aug. 1992, pp. 246-248.
Ekaterina Kanazireva, et al., "Cloning and Overexpression of the Rhodobacter capsulatus hemH Gene," Jul. 1995, pp. 6693-6694.

Affiliated with

Also associated with

Rating

Methods of reducing the levels of protoporphyrin IX in recombina does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of reducing the levels of protoporphyrin IX in recombina, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of reducing the levels of protoporphyrin IX in recombina will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1962295